[go: up one dir, main page]

NZ292991A - Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them - Google Patents

Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them

Info

Publication number
NZ292991A
NZ292991A NZ292991A NZ29299195A NZ292991A NZ 292991 A NZ292991 A NZ 292991A NZ 292991 A NZ292991 A NZ 292991A NZ 29299195 A NZ29299195 A NZ 29299195A NZ 292991 A NZ292991 A NZ 292991A
Authority
NZ
New Zealand
Prior art keywords
tetrahydropyrazolopyridines
pde
phosphodiesterase
tnf
bicyclic
Prior art date
Application number
NZ292991A
Inventor
Allen J Duplantier
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ292991A publication Critical patent/NZ292991A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ292991A 1994-10-20 1995-10-06 Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them NZ292991A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32643494A 1994-10-20 1994-10-20
PCT/IB1995/000847 WO1996012720A1 (en) 1994-10-20 1995-10-06 Bicyclic tetrahydro pyrazolopyridines and their use as medicaments

Publications (1)

Publication Number Publication Date
NZ292991A true NZ292991A (en) 1999-02-25

Family

ID=23272184

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ292991A NZ292991A (en) 1994-10-20 1995-10-06 Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them

Country Status (16)

Country Link
EP (1) EP0787132A1 (en)
JP (1) JPH09511758A (en)
KR (1) KR970707124A (en)
CN (1) CN1050129C (en)
AU (1) AU702105B2 (en)
BR (1) BR9504491A (en)
CZ (1) CZ120097A3 (en)
FI (1) FI954991L (en)
HU (1) HUT77517A (en)
IL (1) IL115667A0 (en)
MX (1) MX9504422A (en)
NO (1) NO971811L (en)
NZ (1) NZ292991A (en)
PL (1) PL319758A1 (en)
WO (1) WO1996012720A1 (en)
ZA (1) ZA958839B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
ES2201299T3 (en) * 1996-06-25 2004-03-16 Pfizer Inc. INDAZOL SUBSTITUTED DERIVATIVES AND ITS USE AS TYPE IV PHOSPHODIESTERASE (PDE) INHIBITORS AND TUMOR NECROSIS FACTOR (TNF) `.
AU6849798A (en) * 1997-05-08 1998-11-27 Pfizer Products Inc. Processes and intermediates for preparing substituted indazole derivatives
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
PT1140941E (en) 1998-12-23 2005-02-28 Bristol Myers Squibb Pharma Co HETEROCYCLICS CONTAINING NITROX AS FACTOR XA INHIBITORS
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
US6326495B2 (en) 1999-04-30 2001-12-04 Pfizer Inc. Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
HU229439B1 (en) 1999-08-21 2013-12-30 Takeda Gmbh Synergistic combination roflumilast and salmeterol
DE60143041D1 (en) * 2000-08-10 2010-10-21 Pfizer Italia Srl Bicyclic pyrazoles are effective as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing them
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
CA2441772A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
CA2444571A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridin-7-ones as factor xa inhi bitors
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
ES2329881T3 (en) 2001-09-21 2009-12-02 Bristol-Myers Squibb Company COMPOUNDS CONTAINING LACTAMA AND DERIVATIVES OF THE SAME AS INHIBITORS OF FACTOR XA.
AU2003244632A1 (en) * 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
FR2857363B1 (en) * 2003-07-10 2007-09-07 Aventis Pharma Sa SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO [3,4-C] PYRIDINES COMPOSITIONS CONTAINING SAME AND USE THEREOF
AR045037A1 (en) * 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
EA014906B1 (en) 2005-12-01 2011-02-28 Элан Фармасьютикалз, Инк. 5-(arylsulfonyl)-pyrazolopiperidines
EP2276769A4 (en) 2008-04-30 2011-08-17 Almqvist Fredrik New peptidomimetic compounds
KR101787116B1 (en) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 Bicyclic pyrazolo-heterocycles
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US10144732B2 (en) 2014-06-06 2018-12-04 Biogen Ma Inc. ATX modulating agents
CN115043768A (en) * 2022-06-20 2022-09-13 新乡市润宇新材料科技有限公司 Method for synthesizing N-aryl pyrrolidine-2-ketone by acid-promoted ring opening of cyclopropyl

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
FR1463883A (en) * 1964-09-08 1966-07-22 Ciba Geigy Process for the preparation of bicyclic triaza-compounds
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
EP0707585A1 (en) * 1993-07-06 1996-04-24 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines

Also Published As

Publication number Publication date
NO971811L (en) 1997-06-18
CN1050129C (en) 2000-03-08
HUT77517A (en) 1998-05-28
CN1161040A (en) 1997-10-01
FI954991A0 (en) 1995-10-19
AU702105B2 (en) 1999-02-11
MX9504422A (en) 1997-04-30
ZA958839B (en) 1997-04-21
PL319758A1 (en) 1997-08-18
NO971811D0 (en) 1997-04-18
KR970707124A (en) 1997-12-01
FI954991A7 (en) 1996-04-21
CZ120097A3 (en) 1998-01-14
JPH09511758A (en) 1997-11-25
EP0787132A1 (en) 1997-08-06
FI954991L (en) 1996-04-21
WO1996012720A1 (en) 1996-05-02
IL115667A0 (en) 1996-01-19
BR9504491A (en) 1997-05-20
AU3531795A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
NZ292991A (en) Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
HUP9903248A3 (en) Indazole derivatives and pharmaceutical compositions containing them with the effect of inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
HUP0001640A3 (en) N6 heterocyclic substituted adenosine derivatives, their use for production of pharmaceutical compositions and pharmaceutical compositions containing them
HUP9901780A3 (en) Imid derivatives as phosphodiesterases and tnf inhibitors and pharmaceutical compositions containing them
IL112496A0 (en) Pharmaceutical compositions comprising inhibitors of poly(adp-ribose) synthetase
HUP0202703A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases and pharmaceutical compositions containing them and their use
HUP0004225A3 (en) Pyridine derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
NZ212104A (en) Benzazepine and benzodiazepine derivatives and pharmaceutical compositions
PH25932A (en) Adenosine derivatives and pharmaceutical compositions containing the same
PL356063A1 (en) Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
ZA936964B (en) Pharmaceutical compositions containing derivatives of nomegestrol and their process of manufacture
HUP9902026A3 (en) Use of bicyclic 4-aralkylaminopyrimidine derivatives for producing pharmaceutical compositions having tyrosine kinase inhibitor effect, novel bicicyclic 4-aralkylaminopirimidine derivatives and pharmaceutical compositions containing them
AU1193092A (en) Granulated pharmaceutical composition and method of obtaining it
HUT64756A (en) Process for the production of quinoxaline derivatives and of pharmaceutical compositions containing them
NZ226445A (en) Aminopyridine derivatives and pharmaceutical compositions containing such
IL105673A0 (en) Purine derivatives and pharmaceutical compositions containing them
IL81833A0 (en) Renin inhibitors,their preparation and pharmaceutical compositions containing them
IL104623A0 (en) Biphenyl-substituted quinoline derivatives and pharmaceutical compositions containing the same
NZ225906A (en) Aristeromycin/adenosine derivatives and pharmaceutical compositions
NZ212103A (en) Benzazepine and benzodiazepine derivatives and pharmaceutical compositions
NZ210671A (en) Ortho-condensed pyrrole derivatives and pharmaceutical compositions
IL72562A0 (en) Quinazoline derivatives and pharmaceutical compositions containing them
NZ216416A (en) Benzazepine derivatives and pharmaceutical compositions
NZ212060A (en) Bicyclic hetrocycles and pharmaceutical derivatives
IL86081A0 (en) Benzazepine derivatives and pharmaceutical compositions containing the same